{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T22:45:17Z","timestamp":1784241917507,"version":"3.55.0"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"34","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,8]]},"DOI":"10.1097\/md.0000000000001296","type":"journal-article","created":{"date-parts":[[2015,8,26]],"date-time":"2015-08-26T20:05:55Z","timestamp":1440619555000},"page":"e1296","source":"Crossref","is-referenced-by-count":2,"title":["Late-Onset Immune Thrombocytopenic Purpura After Withdrawal of Interferon Treatment for Chronic Hepatitis C Infection"],"prefix":"10.1097","volume":"94","author":[{"given":"Chien-Hao","family":"Hsiao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Chih","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wei","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hsueh","family":"Tung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-7-20210309","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1053\/j.gastro.2014.03.003","article-title":"New hepatitis C therapies: the toolbox, strategies, and challenges.","volume":"146","author":"Pawlotsky","year":"2014","journal-title":"Gastroenterology"},{"key":"R3-7-20210309","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1002\/hep.22759","article-title":"Diagnosis, management, and treatment of hepatitis C: an update.","volume":"49","author":"Ghany","year":"2009","journal-title":"Hepatology"},{"key":"R4-7-20210309","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1056\/NEJMra010501","article-title":"Immune thrombocytopenic purpura.","volume":"346","author":"Cines","year":"2002","journal-title":"N Engl J Med"},{"key":"R5-7-20210309","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.2169\/internalmedicine.49.3413","article-title":"Autoimmune thrombocytopenic purpura during pegylated interferon alpha treatment for chronic hepatitis C.","volume":"49","author":"Kim","year":"2010","journal-title":"Intern Med"},{"key":"R6-7-20210309","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1080\/09537100600757935","article-title":"Autoimmune thrombocytopenia induced by PEG-IFN-alpha plus ribavirin in hepatitis C.","volume":"17","author":"Demirturk","year":"2006","journal-title":"Platelets"},{"key":"R7-7-20210309","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/ajh.20270","article-title":"Treatment of immune thrombocytopenia associated with interferon therapy of hepatitis C with the anti-CD20 monoclonal antibody, rituximab.","volume":"78","author":"Weitz","year":"2005","journal-title":"Am J Hematol"},{"key":"R8-7-20210309","doi-asserted-by":"crossref","first-page":"e113","DOI":"10.1016\/j.jinf.2004.10.010","article-title":"Pegylated interferon alpha-2a-associated life-threatening Evans syndrome in a patient with chronic hepatitis C.","volume":"51","author":"Lambotte","year":"2005","journal-title":"J Infect"},{"key":"R9-7-20210309","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/j.1572-0241.2003.07315.x","article-title":"Pegylated interferon-2b-associated autoimmune thrombocytopenia in a patient with chronic hepatitis C.","volume":"98","author":"Sevastianos","year":"2003","journal-title":"Am J Gastroenterol"},{"key":"R10-7-20210309","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1016\/S0168-8278(96)80304-7","article-title":"Immune thrombocytopenia and alpha-interferon therapy.","volume":"25","author":"Dourakis","year":"1996","journal-title":"J Hepatol"},{"key":"R11-7-20210309","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1440-1746.2006.03418.x","article-title":"Late onset autoimmune thrombocytopenia associated with pegylated interferon-alpha-2b plus ribavirin treatment for chronic hepatitis C.","volume":"21","author":"Elefsiniotis","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"key":"R12-7-20210309","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1111\/j.1538-7836.2006.01753.x","article-title":"International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).","volume":"4","author":"Miyakis","year":"2006","journal-title":"J Thromb Haemost"},{"key":"R13-7-20210309","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S0753-3322(99)80095-X","article-title":"Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis.","volume":"53","author":"Dumoulin","year":"1999","journal-title":"Biomed Pharmacother"},{"key":"R14-7-20210309","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1182\/blood-2010-08-302984","article-title":"The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia.","volume":"117","author":"Neunert","year":"2011","journal-title":"Blood"},{"key":"R15-7-20210309","first-page":"841","article-title":"Life-threatening severe immune thrombocytopenia during alpha-interferon therapy for chronic hepatitis C.","volume":"50","author":"Fujii","year":"2003","journal-title":"Hepatogastroenterology"},{"key":"R17-7-20210309","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1046\/j.1365-2141.1998.00722.x","article-title":"dev and significance of anticardiolipin, anti-beta2 glycoprotein I and anti-prothrombin antibodies in chronic hepatitis C.","volume":"101","author":"Leroy","year":"1998","journal-title":"Br J Haematol"},{"key":"R18-7-20210309","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0168-8278(99)80127-5","article-title":"Prevalence of hepatitis C virus infection in patients with antiphospholipid syndrome.","volume":"30","author":"Munoz-Rodriguez","year":"1999","journal-title":"J Hepatol"},{"key":"R19-7-20210309","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1128\/CDLI.7.2.241-244.2000","article-title":"Anticardiolipin antibodies in patients with chronic hepatitis C virus infection: characterization in relation to antiphospholipid syndrome.","volume":"7","author":"Ordi-Ros","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"R20-7-20210309","doi-asserted-by":"crossref","first-page":"2983","DOI":"10.1111\/j.1572-0241.1999.01447.x","article-title":"Anticardiolipin antibodies in patients with liver disease.","volume":"94","author":"Mangia","year":"1999","journal-title":"Am J Gastroenterol"},{"key":"R21-7-20210309","first-page":"370","article-title":"Monoclonal antibody Rituximab for severe immune thrombocytopenia after pegylated interferon for hepatitis C infection.","volume":"4","author":"Papakonstantinou","year":"2014","journal-title":"Hippokratia"},{"key":"R22-7-20210309","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.autrev.2014.12.006","article-title":"Hydroxychloroquine as an anti-thrombotic in antiphospholipid syndrome.","volume":"14","author":"Belizna","year":"2015","journal-title":"Autoimmun Rev"},{"key":"R23-7-20210309","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/nrrheum.2010.47","article-title":"Antiphospholipid syndrome: frequency, main causes and risk factors of mortality.","volume":"6","author":"Espinosa","year":"2010","journal-title":"Nat Rev Rheumatol"},{"key":"R24-7-20210309","doi-asserted-by":"crossref","first-page":"240","DOI":"10.2298\/SARH1004240H","article-title":"Late onset of severe thrombocytopenia during Interferon treatment for chronic hepatitis C infection - case report.","volume":"138","author":"Hajder","year":"2010","journal-title":"Srp Arh Celok Lek"},{"key":"R25-7-20210309","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1053\/gast.2002.36045","article-title":"Peginterferon alone or with ribavirin enhances HCV-specific CD4 T-helper 1 responses in patients with chronic hepatitis C.","volume":"123","author":"Kamal","year":"2002","journal-title":"Gastroenterology"},{"key":"R26-7-20210309","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrrheum.2012.106","article-title":"New insights into mechanisms of therapeutic effects of antimalarial agents in SLE.","volume":"8","author":"Wallace","year":"2012","journal-title":"Nat Rev Rheumatol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000001296","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:47:59Z","timestamp":1620960479000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201508040-00007"}},"subtitle":["A Case Report"],"short-title":[],"issued":{"date-parts":[[2015,8]]},"references-count":24,"journal-issue":{"issue":"34","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000001296","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2015,8]]}}}